The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer
Official Title: Randomized Phase II Open-Label Controlled Study of EMD 72000 (Matuzumab), in Combination With the Chemotherapy Regimen ECX or the Chemotherapy Regimen ECX Alone as First-line Treatment in Subjects With Metastatic Esophago-Gastric Adenocarcinoma
Study ID: NCT00215644
Brief Summary: The purpose of this study is to compare the effectiveness and safety of experimental treatment matuzumab and ECX chemotherapy, with ECX chemotherapy. Participants invited to take part have metastatic cancer of the esophagus (gullet) or stomach.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Research Site, Essen, , Germany
Research Site, Hamburg, , Germany
Research Site, Oldenburg, , Germany
Research Site, Recklinghausen, , Germany
Research Site, A Coruna, , Spain
Research Site, Barcelona, , Spain
Research Site, Cadiz, , Spain
Research Site, Valencia, , Spain
Research Site, Bern, , Switzerland
Research Site, Geneva, , Switzerland
Research Site, Lausanne, , Switzerland
Research Site, St. Gallen, , Switzerland
Research Site, Northwood, Middlesex, United Kingdom
Research Site, Bournemouth, , United Kingdom
Research Site, Cambridge, , United Kingdom
Research Site, Chelmsford, , United Kingdom
Research Site, Guildford, , United Kingdom
Research Site, Leicester, , United Kingdom
Research Site, London, , United Kingdom
Research Site, Newcastle, , United Kingdom
Research Site, Northwood, , United Kingdom
Research Site, Portsmouth, , United Kingdom
Name: Medical Responsible
Affiliation: Merck KGaA, Darmstadt, Germany
Role: STUDY_DIRECTOR